МЕСТО БИСОПРОЛОЛА В ТЕРАПИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ И ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА


Цитировать

Полный текст

Аннотация

Применение блокаторов бета-адренорецепторов приводит к уменьшению риска смерти и тяжелых сосудистых осложнений у больных артериальной гипертензией (АГ), острыми и хроническими формами ишемической болезни сердца (ИБС). Особенно значимо влияние лечения с использованием бета-адреноблокаторов на риск развития фатальных желудочковых аритмий у пациентов с высоким риском внезапной смерти. Высокоселективный бета1-адреноблокатор без собственной симпатомиметической активности бисопролол характеризуется высокой биодоступностью, длительным периодом полувыведения, сбалансированным клиренсом. В клинических исследованиях показана эффективность терапии бисопрололом, выражающаяся в снижении показателей сердечно-сосудистой заболеваемости и смертности при АГ и ИБС.

Об авторах

А А Кириченко

Кафедра терапии РМАПО, Москва

Кафедра терапии РМАПО, Москва

A A Kirichenko

Список литературы

  1. Goldstein S. β-blocking drugs and coronary heart disease. Cardiovasc Drugs Ther 1997;71:219-25.
  2. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005;144(3):317-22.
  3. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta-blockers. J Clin Pharmacol 2003;28(3):179-86.
  4. Brixius K, Bundkirchen A, Bolck B, et al. nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133(8):1330-38.
  5. Leopold G, Pabst J, Ungethum W, et al. Basic pharmacokinetics of bisoprolol, a new highly beta 1 selective adrenoreceptor antagonist. J Clin Pharmacol 1986;26:616-21.
  6. Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother 1997;8:35-43.
  7. Brode O-E. The pharmacology of bisoprolol. Rev Contemp Pharmacother 1997;8:21-33.
  8. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986;8(Suppl. 11):S16-S20.
  9. Cheung WK, Begg E, dutta A, et al. Dose proportionality of bisoprolol in man. Pharm Res 1988;5(Suppl.):S159.
  10. Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997;8:55-67.
  11. Кириченко А.А., Флегентова О.Н., Рязанцев А. и др. Бисогамма в постменопаузе у женщин с артериальной гипертензией и кардиалгией // Врач. 2005. № 8. C. 33-37.
  12. Шилов А.М. Бета-блокатор второго поколения в практике лечения артериальной гипертонии // Фарматека. 2008. C. 8-12.
  13. Gosse P, Roudaut R, Herrero G, et al. β-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990;16(Suppl. 5):145-50.
  14. Frishman W, Bryzinski B, Coulson L, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-68.
  15. Van der Ven LL, et al. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997;1:16-22.
  16. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987;8:103-13.
  17. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987;8(Suppl. M):65-69.
  18. Сидоренко Б.А. β-блокаторы: современныне аспекты применения в кардиологии // Кардиология. 1998. № 2. C. 84-96.
  19. Gibbons RJ, Chatteerjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999;33:2192-97.
  20. van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to choose for stable anginapectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995;47(3):217-23.
  21. Nerol I, Plaza L, Rodrigp F. Bisoprolol in the treatment of chronic stable angina pectoris. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S208-12.
  22. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/AmericanHeart Association task force on practice Guidelines (Commitee on Management of Patientswith Chronic Stable angina). Circulation 1999;99(21):2829-48.
  23. Weber F, Schneider H, von Arnim T, et al. Heart Rate variability and ischemia in patients with coronary heart disease and stable angina pectories; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999;20(1):38-50.
  24. de Muinck ED, Lie KI, von Mengden HJ, et al. bisoprolol pilot studies in myocardial infarction. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S196-200.
  25. Antman EM. ST-elevation myocardial infarction: management. In book: "Braunwald's Heart Disease", 8-th edition 2008;51:1233-99.
  26. Cannon CP, Braunwald E. Unstable angina and non-ST-elevation myiocardial infarction. Item Ch. 53:1319-51.
  27. Hjalmarson A. cardiprotection with beta-adrenoreceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000;95(Supll. 1):I41-45.
  28. MacAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 1977;54(2):235-52
  29. Brand DA, Newcomer LN, Freiberger A, et al. Cardiologist's practices compared with practice guidelines: use of beta-blocade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-36.
  30. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
  31. Funk-Bentano C, Lancart R, Lehenzey JY, et al Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II); a study of the interaction between beta0blocker therapy and occurrence of critical events using analysis of competative risks. Am Heart J 2000;139:262-71.
  32. Hjalmarson A. Prevention of sudden cardiac death with beta-blockers Clin Card 1999;22(Suppl. 5):V11-5.
  33. Ellerbeck EF, Jencks SF, Randorf MJ, et al. Quality of care for Medicare patients with acute myocardial infarction:A for-state pilot study from the cooperative cardiovascular project. JAMA 1995;273:1509-14.
  34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blocade on mortality in high-risk and low - risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
  35. Chen J, Redfort MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Amer Coll Cardiol 2001;7:1950-56.
  36. Терещенко С.Н., Павликова Е.П., Сивков В.И. и др. Применение селективного бета-адреноблокатора бисопрлола у больных острым инфарктом миокарда и сопутствующим хроническим обструктивным бронхитом //Кардиология. 2000. № 9. С. 42-44.
  37. Dorow L, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolo on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986;31:143-47.
  38. Chatterjee SS. the cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc pharmacol 1986;8(Suppl. 1):74-77.
  39. Kjeksus JK, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
  40. Forman DE, Gutierrez Bernal JL, Wei JI. Management of acute myocardial infarction in the very elderly. Am J Med 1992;93:315-26.
  41. Chen J, Marciniac TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. JACC 1999;34:1388-94.
  42. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in tipe 2 diabetes: UKPDS 38. B Med J 1998;317:703-13.
  43. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefullness of beta-blocker therapy in patients with noninsulin dependent diabetes mellitus and coronary arthery disease. Bezafibrate infarction prevention (BIP) Study Groop. Amer J Cardiol 1996;77:1273-77.
  44. Owada A, Suda S, Hata T, et al. The effect of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23(4):305-16.
  45. Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8(Suppl. 11):S96-99.
  46. Heinemann I, Heise T, Ampudia J, et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Europ Heart J 1995;25:595-600.
  47. Schouten O, Poldermans D, Visser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 2004;148(6):1047-52.
  48. Vulpis V, Antonacci A, Prandi P, et al. The effect of bisoprolol and atenolo on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991;82:189-93.
  49. Fogari R, Zoppi A, Tettamanti F, et al. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duratuon of treatment and lipid status befor treatment. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S76-S80.
  50. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987;32:77-80.
  51. Bulpitt CJ, Connor M, Schulte M, et al. Bisiprolol and nifedipine retard in elderly hypertensive patients : effect on quality of life. J Hum hypertens 2000;14(3):205-12.
  52. Prisant LM, Weir MR, Frishman WH, et al. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enelapril,amlodipine, placebo or bisoprolol/hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22-26.
  53. Bulpitt CJ, Connor M, Schulte M, et al. Bisiprolol and nifedipine retard in elderly hypertensive patients : effect on quality of life. J Hum hypertens 2000;14(3):205-12.
  54. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2290&mid=1085056570&magid=172&full=1

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2009

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах